| Related Articles |
High-Density Lipoprotein Infusions.
Cardiol Clin. 2018 May;36(2):311-315
Authors: Takata K, Di Bartolo BA, Nicholls SJ
Abstract
High-density lipoproteins (HDLs) have presented an attractive target for development of new therapies for cardiovascular prevention on the basis of epidemiology and preclinical studies demonstrating their protective properties. Development of HDL mimetics provides an opportunity to administer functional HDL. However, clinical trials have produced variable results, with no evidence to date that they reduce cardiovascular events. This article reviews development programs of HDL mimetics.
PMID: 29609760 [PubMed - in process]